United Therapeutics (NASDAQ:UTHR) CFO Sells $5,274,800.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

James Edgemond also recently made the following trade(s):

• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00.

United Therapeutics Stock Down 1.8%

NASDAQ:UTHR opened at $522.83 on Friday. The stock has a market cap of $22.92 billion, a price-to-earnings ratio of 18.74, a PEG ratio of 1.92 and a beta of 0.84. The company’s 50 day moving average price is $495.95 and its 200-day moving average price is $472.65. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $549.50.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the business earned $6.19 EPS. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Torren Management LLC bought a new position in United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management grew its stake in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $31,000. Wilmington Savings Fund Society FSB increased its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of United Therapeutics during the 4th quarter valued at about $48,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of research analyst reports. Cantor Fitzgerald upped their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. UBS Group boosted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $549.91.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.